

CORCEPT THERAPEUTICS INC  
Form 8-K  
March 23, 2007

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 19, 2007**

**Corcept Therapeutics Incorporated**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**000-50679**  
(Commission File Number)

**77-0487658**  
(I.R.S. Employer Identification No.)

**149 Commonwealth Drive**  
**Menlo Park, CA 94025**  
(Address of principal executive offices, with zip code)

**(650) 327-3270**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
- 
-

**Item 8.01**

**Other Events.**

On March 19, 2007 Corcept Therapeutics Incorporated issued a press release announcing that Study 06, the last of three Phase 3 trials evaluating CORLUX® for treating the psychotic features of Psychotic Major Depression, did not achieve statistical significance with respect to its primary endpoint.

**Item 9.01**

**Financial Statements and Exhibits.**

Exhibit 99.1 Press Release dated March 19, 2007

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CORCEPT THERAPEUTICS INCORPORATED**

Date: **March 23, 2007**

By:

/s/ Fred Kurland  
**Fred Kurland**  
**Chief Financial Officer**

**Exhibit Index**

<u>Exhibit No.</u>	<u>Description</u>
<u>99.1</u>	Study 06 Results